Press-release for stocks for PLRX

Prices are updated after-hours

symbols : PLRX

save search

Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
Published: 2022-07-10 (Crawled : 00:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| 49.32% | O: 80.29% H: 43.66% C: 43.66%
pln-7480 fibrosis trial therapeutics positive phase 2b

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
Published: 2023-01-22 (Crawled : 20:20) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -41.09% | O: 55.66% H: 4.17% C: -13.58%
fibrosis trial therapeutics positive phase 2b

Pliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -30.32% | O: 15.61% H: 9.86% C: -12.91%
phase 2 fibrosis positive results trial imaging phase 2b

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -6.62% | O: 10.0% H: 2.94% C: -11.46%
update therapeutics financial results

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ARVL | News | $0.49 0.37% 2.5M

Manufacturing

| -54.35% | O: -1.24% H: 0.0% C: 0.0%
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -9.05% | O: 7.89% H: 11.25% C: 5.98%
liver positive fibrosis bexotegrast trial therapeutics

Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
Published: 2023-09-25 (Crawled : 20:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -9.05% | O: 7.89% H: 11.25% C: 5.98%
trial therapeutics

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
Published: 2024-02-27 (Crawled : 21:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -22.95% | O: 4.59% H: 0.0% C: -7.67%
update therapeutics financial results

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
Published: 2023-11-13 (Crawled : 22:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| 3.19% | O: 4.05% H: 0.6% C: -1.5%
meeting liver therapeutics

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
Published: 2023-03-09 (Crawled : 00:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -53.59% | O: 3.43% H: 0.0% C: -5.31%
therapeutics financial update results

Pliant Therapeutics to Participate in Upcoming Investor Conferences
Published: 2022-11-15 (Crawled : 13:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -35.25% | O: 2.64% H: 5.71% C: 3.14%
therapeutics

Pliant Therapeutics to Participate in Annual Needham Virtual Healthcare Conference
Published: 2021-04-05 (Crawled : 12:15) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -63.06% | O: 2.51% H: 4.01% C: 2.42%
annual needham conference annual needham virtual healthcare conference needham virtual healthcare conference therapeutics

Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
Published: 2023-09-15 (Crawled : 12:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -18.05% | O: 0.19% H: 0.25% C: -1.23%
NKTR | News | $1.345 -9.73% -10.78% 3.3M

Health Technology

| 123.52% | O: 2.01% H: 7.57% C: 3.79%
therapeutics

Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight
Published: 2024-04-03 (Crawled : 22:00) - prnewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -8.11% | O: 1.87% H: 3.4% C: -1.02%
fibrosis therapeutics growth market

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Published: 2022-09-01 (Crawled : 14:20) - biospace.com/
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -31.22% | O: 1.76% H: 4.84% C: 3.47%
pln-7480 fibrosis trial therapeutics review positive phase 2b

Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones
Published: 2022-01-11 (Crawled : 16:00) - biospace.com/
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| 12.47% | O: 1.61% H: 0.0% C: 0.0%
milestone pln-7480

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Published: 2023-05-09 (Crawled : 20:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -41.09% | O: 1.55% H: 3.59% C: 0.74%
update therapeutics financial results

Pliant Therapeutics to Participate in Upcoming Investor Events
Published: 2023-05-10 (Crawled : 12:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K

Health Technology

| -41.09% | O: 1.55% H: 3.59% C: 0.74%
therapeutics